Brokers Issue Forecasts for ADMA Biologics FY2024 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA) – Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for ADMA Biologics in a research report issued on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of $0.52 for the year, up from their prior forecast of $0.50. Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.52 per share.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the business posted $0.01 EPS.

Several other research firms have also weighed in on ADMA. HC Wainwright lifted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James lifted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Up 2.4 %

Shares of ADMA opened at $16.71 on Wednesday. The company has a market capitalization of $3.95 billion, a PE ratio of 59.68 and a beta of 0.76. ADMA Biologics has a 12 month low of $4.82 and a 12 month high of $23.64. The stock’s 50-day moving average price is $19.23 and its two-hundred day moving average price is $17.23. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hollencrest Capital Management bought a new stake in ADMA Biologics during the 3rd quarter valued at approximately $30,000. Larson Financial Group LLC purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $31,000. National Bank of Canada FI purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $35,000. GAMMA Investing LLC raised its stake in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in ADMA Biologics during the 2nd quarter valued at $29,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.